Table 1 Characteristics of Eligible Patients.

From: Nomograms to predict the long-term prognosis for non-metastatic invasive lobular breast carcinoma: a population-based study

Characteristics

Overall

Training cohort

Validation cohort

P-value

(N=31,451)

(N =22,017)

(N = 9434)

Age (%)

0.2

 22–65 years

18,727 (59.5%)

13,042 (59%)

5685 (60%)

 

 66–78 years

9352 (29.7%)

6614 (30%)

2738 (29%)

 

 ≥ 79 years

4063 (10.7%)

2361 (11%)

1011 (11%)

 

Race (%)

0.3

 White

27,203 (86.5%)

19,073 (87%)

8130 (86%)

 

 Black

2273 (7.2%)

1560 (7.1%)

713 (7.6%)

 

 Other†

1975 (6.3%)

1384 (6.3%)

591 (6.3%)

 

Marriage (%)

> 0.9

 Married

19,078 (60.7%)

13,355 (61%)

5723 (61%)

 

 Unmarried

3840 (12.2%)

2688 (12%)

1152 (12%)

 

 Separated

8533 (27.1%)

5974 (27%)

2559 (27%)

 

Primary site (%)

0.2

 UO

11,370 (36.2%)

7978 (36%)

3392 (36%)

 

 CP

1780 (5.7%)

1234 (5.6%)

546 (5.8%)

 

 UI

3209 (10.2%)

2275 (10%)

934 (9.9%)

 

 LI

1154 (3.7%)

829 (3.8%)

325 (3.4%)

 

 NP

116 (0.4%)

83 (0.4%)

33 (0.3%)

 

 LO

2275 (7.2%)

1629 (7.4%)

646 (6.8%)

 

 AT

146 (0.5%)

106 (0.5%)

40 (0.4%)

 

 OL

7153 (22.7%)

4923 (22%)

2230 (24%)

 

 NOS

4248 (13.5%)

2960 (13%)

1288 (14%)

 

Laterality (%)

0.1

 Left

16,167 (51.4%)

11,250 (51%)

4917 (52%)

 

 Right

15,284 (48.6%)

10,767 (49%)

4517 (48%)

 

Grade (%)

0.5

 I/II

28,544 (90.8%)

19,997 (91%)

8547 (91%)

 

 III/IV

2907 (9.2%)

2020 (9.2%)

887 (9.4%)

 

ER (%)

0.3

 Positive

30,691 (97.6%)

21,497 (98%)

9194 (97%)

 

 Negative

760 (2.4%)

520 (2.4%)

240 (2.5%)

 

PR (%)

0.5

 Positive

26,262 (83.5%)

18,406 (84%)

7856 (83%)

 

 Negative

5189 (16.5%)

3611 (16%)

1578 (17%)

 

HER2 (%)

0.2

 Negative

792 (2.5%)

566 (2.6%)

226 (2.4%)

 

 Positive

17,045 (54.2%)

11,858 (54%)

5187 (55%)

 

 Unknown

17,237 (43.3%)

9593 (44%)

4021 (43%)

 

Tumor size (%)

0.4

 ≤ 20 mm

15,682(49.9%)

10,989 (50%)

4693 (50%)

 

 20–50 mm

10,669(33.9%)

7496 (34%)

3173 (34%)

 

 ≥ 50 mm

5100(16.2%)

3532(16%)

1568(17%)

 

LNR (%)

0.7

 0.00–0.53

27,787 (88.4%)

19,462 (88%)

8325 (88%)

 

 0.54–1

3664 (11.6%)

2555 (12%)

1109 (12%)

 

Surgery (%)

0.2

 Mastectomy

17,021 (54.1%)

11,840 (54%)

5181 (55%)

 

 Breast conservation

14,338 (45.6%)

10,115 (46%)

4223 (45%)

 

 NOS

12 (0%)

8 (<0.1%)

4 (<0.1%)

 

 No/unknown

80 (0.3%)

54 (0.2%)

26 (0.3%)

 

Radiation (%)

0.9

 Yes

16,807 (53.4%)

11,771 (53%)

5036 (53%)

 

 No/unknown

14644 (46.6%)

10,246 (47%)

4398 (47%)

 

Chemotherapy (%)

>0.9

 No/unknown

19,862 (63.2%)

13,900 (63%)

5962 (63%)

 

 Yes

14,252 (36.8%)

8117 (37%)

3472 (37%)

 

CS stage (%)

0.2

 Localized

19,424 (61.8%)

13,646 (62%)

5778 (61%)

 

 Regional

14,253 (38.2%)

8371 (38%)

3656 (39%)

 

ILC specific death (%)

0.5

 No

28,034 (89.1%)

19,641 (89%)

8393 (89%)

 

 Yes

3417 (10.9%)

2376 (11%)

1041 (11%)

 

All cause death (%)

>0.9

 No

23,497 (74.7%)

16,452 (75%)

7045 (75%)

 

 Yes

7954 (25.3%)

5565 (25%)

2389 (25%)

 

Survival (months)

 Median (Range), [IQR]

101 (1–203), [72–138]

101 (1–203), [72–138]

99 (1–203), [71–136]

 
  1. Other† American Indian, Alaska Native, Asian, and Pacific Islander, NP nipple, CP central portion, UI upper-inner quadrant, LI Lower-inner quadrant, UO upper-outer quadrant, LO lower-outer quadrant, AT axillary tail, OL overlapping lesion, NOS not otherwise specific, ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor 2-neu, LNR lymph node ratio, CS Stage Combined summary stage, ILC Invasive lobular breast carcinoma, IQR interquartile range.
Back to article page